Diffuse large B‑cell lymphoma and monoclonal gammopathy secondary to immune thrombocytopenic purpura: A case report

Ren,Liwei; Liu,Wenhui; Wu,Tao; Xue,Feng; Mao,Dongfeng; Yu,Lingling; Bai,Hai

doi:10.3892/ol.2023.13823

Diffuse large B‑cell lymphoma and monoclonal gammopathy secondary to immune thrombocytopenic purpura: A case report

Authors:
- Liwei Ren
- Wenhui Liu
- Tao Wu
- Feng Xue
- Dongfeng Mao
- Lingling Yu
- Hai Bai
View Affiliations

Affiliations: Department of Hematology, The 940th Hospital of The Joint Logistics Support Force of The Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China
Published online on: April 19, 2023 https://doi.org/10.3892/ol.2023.13823
Article Number: 237
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study reports the case of a patient with diffuse large B‑cell lymphoma (DLBCL) and monoclonal gammopathy (MG) secondary to immune thrombocytopenia purpura (ITP). The clinical diagnoses and investigations of this case are reported. To the best of our knowledge, this is the first study to report DLBCL and MG secondary to ITP. The patient presented with a rare constellation of diseases, which made the diagnosis and treatment difficult for the physicians. The patient was followed up for 10 years using the morphological examination of bone marrow cells after chemotherapy, and currently continues with follow‑up examinations. Treatments and prognoses for ITP, DLBCL and MG are common. However, treatments and prognoses are unclear for patients with all three conditions. The different clinical manifestations and disease processes of DLBCL and MG secondary to ITP cause difficulties for physicians in terms of treatment and prognosis. The present case report describes the comprehensive evaluation, diagnosis and treatment of a patient with DLBCL and MG secondary to, and concurrent with, ITP.

View Figures

View References

1	Fattizzo B and Barcellini W: Autoimmune cytopenias in chronic lymphocytic leukemia: Focus on molecular aspects. Front Oncol. 9:14352020. View Article : Google Scholar : PubMed/NCBI
2	Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, Cortelezzi A, Laurenti L, Pogliani EM, Pedotti P, et al: Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 91:1689–1692. 2006.PubMed/NCBI
3	Fallah M, Liu X, Ji J, Försti A, Sundquist K and Hemminki K: Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study. Ann Oncol. 25:2025–2030. 2014. View Article : Google Scholar : PubMed/NCBI
4	Visco C, Ruggeri M, Laura Evangelista M, Stasi R, Zanotti R, Giaretta I, Ambrosetti A, Madeo D, Pizzolo G and Rodeghiero F: Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 111:1110–1116. 2008. View Article : Google Scholar : PubMed/NCBI
5	Mittal S, Blaylock MG, Culligan DJ, Barker RN and Vickers MA: A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 93:151–152. 2008. View Article : Google Scholar : PubMed/NCBI
6	Kyle RA and Lust JA: Monoclonal gammopathies of undetermined significance. Semin Heamatol. 26:176–200. 1989.PubMed/NCBI
7	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
8	Liu Y and Barta SK: Diffuse large B-cell lymphoma: 2019 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 94:604–616. 2019. View Article : Google Scholar : PubMed/NCBI
9	Papageorgiou SG, Thomopoulos TP, Spathis A, Bouchla A, Glezou I, Stavroulaki G, Gkontopoulos K, Bazani E, Foukas PG and Pappa V: Prognostic significance of monoclonal gammopathy in diffuse large B-cell lymphoma. Hematol Oncol. 37:634–637. 2019. View Article : Google Scholar : PubMed/NCBI
10	Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA and Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting. Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–3849. 1999. View Article : Google Scholar : PubMed/NCBI
11	Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
12	Cooper N: State of the art-how I manage immune thrombocytopenia. Br J Haematol. 177:39–54. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zufferey A, Kapur R and Semple JW: Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 6:162017. View Article : Google Scholar : PubMed/NCBI
14	Olsson B, Ridell B, Jernås M and Wadenvik H: Increased number of B-cells in the red pulp of the spleen in ITP. Ann Hematol. 91:271–277. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chen JF, Yang LH, Chang LX, Feng JJ and Liu JQ: The clinical significance of circulating B cells secreting anti-glycoprotein IIb/IIIa antibody and platelet glycoprotein IIb/IIIa in patients with primary immune thrombocytopenia. Hematology. 17:283–290. 2012. View Article : Google Scholar : PubMed/NCBI
16	Li X, Zhong H, Bao W, Boulad N, Evangelista J, Haider MA, Bussel J and Yazdanbakhsh K: Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood. 120:3318–3325. 2012. View Article : Google Scholar : PubMed/NCBI
17	Aslam R, Segel GB, Burack R, Spence SA, Speck ER, Guo L and Semple JW: Splenic lymphocyte subtypes in immune thrombocytopenia: Increased presence of a subtype of B-regulatory cells. Br J Haematol. 173:159–160. 2016. View Article : Google Scholar : PubMed/NCBI
18	Min YN, Wang CY, Li XX, Hou Y, Qiu JH, Ma J, Shao LL, Zhang X, Wang YW, Peng J, et al: Participation of B-cell-activating factor receptors in the pathogenesis of immune thrombocytopenia. J Thromb Haemost. 14:559–571. 2016. View Article : Google Scholar : PubMed/NCBI
19	Miltiadous O, Hou M and Bussel JB: Identifying and treating refractory ITP: Difficulty in diagnosis and role of combination treatment. Blood. 135:472–490. 2020. View Article : Google Scholar : PubMed/NCBI
20	De Rossi G, Granati L, Girelli G, Gandolfo G, Arista MC, Martelli M, Conti L, Marini R, La Tagliata R, Leone R, et al: Incidence and prognostic significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol (1978). 30:403–406. 1988.PubMed/NCBI
21	De Rossi G, Granati L, Girelli G, Gandolo G, Perrone P, Martelli M, Conti L, Marini R, Pastorelli D, Coluzzi S, et al: Prognostic value of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Tumori. 77:100–104. 1991. View Article : Google Scholar : PubMed/NCBI
22	Garvey MB and Freedman J: Indirect platelet radioactive antiglobulin test in patients with lymphoproliferative disease. J Lab Clin Med. 107:123–128. 1986.PubMed/NCBI
23	Liu EB, Zhang PH, Li ZQ, Sun Q, Yang QY, Fang LH, Sun FJ and Qiu LG: Clinicopathologic features of lymphoplasmacytic lymphoma. Zhonghua Bing Li Xue Za Zhi. 39:308–312. 2010.(In Chinese). PubMed/NCBI
24	Lechman HA, Lehman LO, Rutagi PK, Rustgi RN, Plunkett RW, Farolino DL, Conway J and Logue GL: Complement-mediated autoimmune thrombocytopenia. Monoclonal IgM antiplatelet antibody associated with lymphoreticular malignant disease. N Engl J Med. 316:194–198. 1987.
25	Kuznetsov AI, Ivanov AL, Idelson LI and Mazurov AV: Mechanisms of thrombocytopenia in patients with lymphoproliferative diseases. Eur J Haematol. 49:113–118. 1992. View Article : Google Scholar : PubMed/NCBI
26	Myers TJ, Kim BK, Steiner M and Baldini MG: Platelet-associated complement C3 in immune thrombocytopenic purpura. Blood. 59:1023–1028. 1982. View Article : Google Scholar : PubMed/NCBI
27	Kaiho T, Miyazaki M, Iinuma K, Ito H, Koyama T, Nakagawa K and Nakajima N: Long-term prognosis of idiopathic thrombocytopenic purpura treated by partial splenic embolization. Nihon Geka Gakkai Zasshi. 94:383–393. 1993.(In Japanese). PubMed/NCBI
28	Vardhana SA, Sauter CS, Matasar MJ, Zelenetz AD, Galasso N, Woo KM, Zhang Z and Moskowitz CH: Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 176:591–599. 2017. View Article : Google Scholar : PubMed/NCBI
29	Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010. View Article : Google Scholar : PubMed/NCBI
30	Witzig TE, Maurer MJ, Stenson MJ, Allmer C, Macon W, Link B, Katzmann JA and Gupta M: Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. Am J Hematol. 89:417–422. 2014. View Article : Google Scholar : PubMed/NCBI
31	Kaseb H, Annamaraju P and Babiker HM: Monoclonal gammopathy of undetermined significance. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023
32	Wright DH: Malignant lymphomas other than Hodgkin's disease: Histology, cytology, ultrastructure, immunology. J Clin Pathol. 32:4141979. View Article : Google Scholar : PubMed/NCBI
33	Economopoulos T, Papageorgiou S, Pappa V, Papageorgiou E, Valsami S, Kalantzis D, Xiros N, Dervenoulas J and Raptis S: Monoclonal gammopathies in B-cell non-Hodgkin's lymphomas. Leuk Res. 27:505–508. 2003. View Article : Google Scholar : PubMed/NCBI
34	Kim YR, Kim SJ, Cheong JW, Kim Y, Jang JE, Lee JY, Min YH, Song JW, Yang WI and Kim JS: Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. Ann Hematol. 93:1867–1877. 2014. View Article : Google Scholar : PubMed/NCBI
35	Li Y, Wang L, Zhu HY, Liang JH, Wu W, Wu JZ, Xia Y, Fan L, Li JY and Xu W: Prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma. Br J Haematol. 182:131–134. 2018. View Article : Google Scholar : PubMed/NCBI
36	Zhang Y, Wei Z, Li J, Gao R and Liu P: Monoclonal gammopathies regardless of subtypes are associated with poor prognosis of diffuse large B-cell lymphoma: A STROBE-compliant article. Medicine (Baltimore). 97:e117192018. View Article : Google Scholar : PubMed/NCBI
37	Cox MC, Di Napoli A, Fabbri A, Cencini E and Ruco L: The significance of serum immunoglobulin paraprotein in diffuse large B-cell lymphoma. Br J Haematol. 182:741–742. 2018. View Article : Google Scholar : PubMed/NCBI